Engflag

Flucort N

Quick links to important sections

Flucort N

Selected form

Flucort N_EN

Method of action: Antiallergic, Anti-Inflammatory, Antipruritic, Corticosteroids, Dermatological Preparations, Ophthalmologicals

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucort N

Property Description
Active Ingredients Fluocinolone Acetonide, Neomycin
Form Cream, Ointment, Topical Solution
Pharmacological Class Corticosteroid / Aminoglycoside Antibiotic Combination
Common Use Managing inflammatory conditions complicated by bacteria
Origin Synthetic and Derived/Semi-synthetic

What Type of Medicine Is Flucort N?

Flucort N is classified as a specialized topical dermatological combination product, meaning it is formulated for direct cutaneous application and incorporates two distinct active medicinal agents. It belongs to the pharmacological class of a corticosteroid combined with an aminoglycoside antibiotic. This dual-action nature is clinically recognized for providing comprehensive local treatment, distinguishing it from medications that address only a single aspect of skin pathology.

The medicine is typically provided as a cream or ointment dosage form, allowing for localized, high-concentration delivery of the active components. Flucort N is often a prescription-only medication, indicating that the potency of the steroid and the inclusion of an antibiotic necessitate medical supervision during use.

Flucort N's Active Ingredients and Dual-Action Composition

The composition features two International Nonproprietary Name (INN) components: Fluocinolone Acetonide and Neomycin. Fluocinolone Acetonide is a powerful synthetic fluorinated corticosteroid, which is pharmacologically confirmed to be effective in suppressing localized inflammatory responses. This type of steroid is fundamental for rapidly reducing swelling and redness on the skin. Neomycin is an aminoglycoside antibiotic intended to prevent or control bacterial growth on the skin surface.

The dual-action formula means the medicine acts on two fronts simultaneously. The corticosteroid component efficiently reduces the symptoms of inflammation, while the antibiotic component provides crucial coverage against the susceptible bacteria that frequently complicate the skin disorder.

General Purpose: Targeting Inflammation and Bacterial Presence

The general purpose of Flucort N is to manage inflammatory skin conditions where there is an established or significant risk of concurrent bacterial infection. This product is generally applied in scenarios where conditions like dermatitis have been compromised by scratching and subsequent bacterial colonization. The formulation is intended to provide rapid antipruritic (anti-itch) relief and diminish inflammation. This combination of anti-inflammatory and anti-infective action is essential for interrupting the cycle where inflammation makes the skin vulnerable to bacteria, and bacteria worsen the inflammation.

Regulatory References

  1. NIH confirms

What side effects are possible with Flucort N?

Possible Side Effects and Safety Information

The safety profile for Flucort N, a combination product containing a potent corticosteroid (Fluocinolone Acetonide) and an antibiotic (Neomycin), is characterized by both local effects and the potential for serious systemic absorption risks, as documented in official regulatory labeling.

Adverse Reactions and Frequency Classification

Adverse reactions are primarily associated with the individual components. Common local effects officially listed in regulatory documents include burning, stinging, pruritus (itching), and irritation at the application site. Reactions with an uncommon or incidence not known classification include various dermatological changes such as skin atrophy (thinning), striae (stretch marks), folliculitis, and telangiectasias.

Serious Systemic Risks

Although primarily a topical medication, the risk of systemic absorption exists, which is the basis for documenting serious adverse reactions. The most significant risks include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome from the corticosteroid component. The Neomycin component carries the documented potential for ototoxicity (hearing damage) and nephrotoxicity (kidney damage) if systemic absorption is significant, such as when applied to large areas or broken skin.

Safety Considerations Based on Exposure and Population

Official labeling defines specific safety constraints and population vulnerabilities. Pediatric patients are officially noted to be more susceptible to systemic toxicity (HPA axis suppression) due to their larger skin surface area to body weight ratio. The label also notes that risks, including skin atrophy and systemic effects, are associated with prolonged use and the use of occlusive dressings, which significantly increase absorption. The product should not be used in the external auditory canal if the eardrum is perforated due to the documented risk of Neomycin-related ototoxicity.

Overdose and Emergency Response

Flucort N Overdose and When to Seek Help

Because Flucort N is a topical preparation, an acute overdose is unlikely to cause severe symptoms from a single, excessive application. However, using the medication in large amounts, over extensive areas of the body, for prolonged periods, or under occlusive dressings significantly increases the systemic absorption of its active ingredients, fluocinolone acetonide and neomycin sulfate. This systemic absorption can lead to potential toxicities.

Potential Overdose Effects

Active Component Potential Systemic Effects from Excessive Use
Fluocinolone (Corticosteroid) Reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing's syndrome (e.g., facial puffiness, weight gain), hyperglycemia (high blood sugar), and glucosuria (sugar in the urine).
Neomycin (Antibiotic) Ototoxicity (damage to hearing/balance) and Nephrotoxicity (kidney damage), particularly if absorbed through broken skin or large surface areas.

When to Seek Immediate Medical Help

Immediate medical attention should be sought if the product is accidentally swallowed. Additionally, contact emergency services or a poison control center if you experience signs of significant systemic absorption or a severe allergic reaction, such as difficulty breathing, swelling of the face, lips, tongue, or throat, or changes in hearing or urination patterns. If HPA axis suppression is suspected (e.g., unusual tiredness, weakness, or nausea), consult your healthcare provider promptly for evaluation and testing.

Therapeutic Uses of Flucort N

What Flucort N Treats: Main Uses and Benefits

Flucort N is a specialized topical treatment primarily used to manage conditions involving inflammatory or irritative states that are complicated by, or at high risk of, bacterial presence. The core use is centered on the dual necessity of reducing inflammation and addressing bacterial colonization.

The medication is commonly used across domains where additional symptomatic support is needed to manage conditions like steroid-responsive dermatoses, including specific forms of eczema (e.g., atopic, seborrhoeic) and dermatitis, as well as psoriasis and lichen planus. The corticosteroid component is specifically included for its role in easing challenging symptoms of various skin conditions.

This treatment is typically applied during phases when symptoms become more noticeable, particularly when intense redness, localized swelling, and persistent, irritating itching (pruritus) are present alongside bacterial contamination. The support provided can assist with stability during symptomatic episodes by supporting the moderation of the inflammatory reaction and managing bacterial presence.

“The approach is relevant for helping to manage the cycle of irritation and scratching by easing the intense physical discomfort while also managing the complicating bacterial presence.”

Quick Fact: Relief for Intense Itching The medication plays a role in managing symptoms that interfere with daily comfort, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Flucort N?

This section details the officially documented population eligibility and restrictions for Flucort N (Fluocinolone Acetonide/Neomycin), based strictly on governmental regulatory labeling.

Contraindicated Populations

Flucort N is contraindicated and must not be used by patients with a history of hypersensitivity (allergy) to Fluocinolone Acetonide, Neomycin, or any other component of the preparation. Additionally, the medicine is contraindicated for application in the external auditory canal if there is a perforated eardrum.

Use is not recommended in the presence of certain non-bacterial skin diseases, such as viral infections (e.g., herpes simplex) or fungal infections.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Pediatric Patients Demonstrate greater susceptibility to systemic toxicity (HPA axis suppression). Administration must be limited to the least amount required. Safety is not established in infants younger than 3 months.
Pregnancy Use is conditional: only if the potential benefit justifies the potential risk to the fetus. Must not be extensive or prolonged (FDA Category C).
Lactation Requires caution. Application to the breast/nipple area must be avoided.
Systemic Risk Conditions Use requires caution in patients with pre-existing conditions such as liver disease, kidney disease, or diabetes (due to potential for systemic absorption).

Use is also restricted on large body surface areas, under occlusive dressings, and generally on the face, groin, or axillae.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with other medicines are defined by the potential for systemic absorption of Flucort N's active components, Fluocinolone Acetonide and Neomycin. The official regulatory profile does not document specific CYP-enzyme or transporter-mediated interactions with this topical formulation.

A formal restriction exists regarding co-administration with other aminoglycoside antibiotics due to the documented potential for allergic cross-reactions and cross-sensitivity. Hypersensitivity to any component of the preparation is also a formal restriction.

The systemic absorption of the corticosteroid component establishes a pharmacodynamic antagonism risk with systemic anti-diabetic agents, as the steroid effect may induce hyperglycemia. Furthermore, the absorption of Neomycin creates a risk of a pharmacodynamic additive effect with other systemic medicinal products known to cause ototoxicity or nephrotoxicity.

These pharmacodynamic risks are dependent on the magnitude of systemic exposure. Conditions of application that are officially documented to significantly increase systemic exposure include the use of occlusive dressings, application over large surface areas, and prolonged use. Pediatric patients are noted to be more susceptible to these systemic effects due to proportionally greater absorption.

Mechanism of Action

How Flucort N Works

Flucort N engages a dual mechanistic approach by simultaneously modulating the inflammatory signaling pathway and inhibiting bacterial protein synthesis. This combination engages mechanisms that modulate inflammatory mediators and limit microbial replication.

Modulation via Glucocorticoid Receptor Agonism

The steroid component, Fluocinolone Acetonide, functions as an agonist by binding to the Glucocorticoid Receptor (GR) inside cells. This binding triggers a molecular cascade that culminates in the resulting inhibition of the Phospholipase A2 enzyme. By blocking this early step, the molecule reduces the creation of the inflammatory signals, prostaglandins and leukotrienes. This mechanism modulates heightened pathway activity, which results in the physiological reduction of local vasodilation, fluid leakage, and pruritogenic signaling.

Inhibition of Bacterial Protein Synthesis

The antibiotic component, Neomycin, operates by penetrating susceptible bacteria and binding irreversibly to their 30S ribosomal subunit. This action disrupts the bacterial protein synthesis pathway, causing the misreading of genetic code and the production of faulty, non-functional proteins. This mechanism leads to the bactericidal action (bacterial cell death), thereby modulating the local microbial balance.

Dosage and Administration Information

How Flucort N is Used: Official Administration Guidelines

Flucort N is a combination product containing Fluocinolone Acetonide and Neomycin. The administration details for this medication must be followed precisely to ensure correct application.

Administration Protocol

Administration Scope Detail
Route of Administration Topical (or Cutaneous); intended for external use only.
Dosing Schedule Apply an appropriate amount or a thin layer to cover the affected skin area. The medication must be gently rubbed in completely.
Frequency and Timing The standard schedule is typically two to four times daily, as directed by a healthcare professional.
Preparation Requirements The affected skin surface should be cleaned and dried prior to application.
Special Procedural Conditions Avoid contact with the eyes, mouth, and nose during application. Hands must be washed after use unless the hands are the area being treated.

Duration and Specific Population Rules

Course Duration: Flucort N is designated for short-term treatment. Continuous use should not normally exceed 14 days. Use must be discontinued if the condition persists beyond the maximum recommended duration.

Age-Group and Site Rules:

  • Pediatric Use: Treatment in children requires the smallest effective amount for the shortest possible duration.
  • Face and Sensitive Areas: Use on the face should be strictly limited and generally not extended beyond five days.
  • Occlusion: Do not use occlusive dressings (e.g., tight bandages, plastic pants) over the treated area, especially in infants, unless explicitly instructed by a physician.

This structured approach defines the standardized manner for applying Flucort N, ensuring correct technique and adherence to time limits.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flucort N

Evidence for Use in Conditions Characterized by Heightened Symptom Activity

Flucort N was evaluated in studies conducted during periods of increased symptom activity in conditions where skin inflammation is complicated by the presence of bacteria. The primary research available includes short-term Randomized Controlled Trials (RCTs). The trials research examined several key outcomes linked to inflammatory or irritative states in subjects receiving the product. Researchers looked for changes in physical signs like redness (erythema) and swelling (oedema), and they focused on patient-reported outcomes describing perceived discomfort, such as the severity of itching (pruritus).

Studies reported measurements of symptom changes across the short follow-up period. The evidence contributes to the broader evidence landscape regarding short-term changes observed during acute episodes. However, the data describe patterns related to short-term changes only, and comparative evidence is lacking to fully establish whether a difference exists between the combination and the steroid component alone after the initial days of treatment.

Follow-up Durations and Gaps in Long-Term Data

The majority of studies for this combination product have follow-up durations that were limited, typically ranging from seven to fourteen days. This means the research primarily provides insight into short-term changes that occur during the initial phase of an acute flare-up.

There is limited information for long-term outcomes when using the combination. Since the research focuses on acute episodes, the data are still emerging regarding the durability of the observed changes. Research does not offer clear insight into outcomes related to systemic or functional imbalance that may arise from use beyond the studied short durations, which is a key area of uncertainty.

Research Findings in Specific Groups

The research was evaluated in a population consisting mostly of adult patients. While the primary focus was observed in the adult population, Flucort N was studied for use in pediatric subjects as well.

It is important to note that the results apply only to the populations studied, and the evidence quality may vary across studies. The evidence indicates that data for certain groups remain insufficient for researchers to draw wide-ranging conclusions.

Key Studies & References

  1. Fluocinolone Topical: MedlinePlus Drug Information
  2. Neomycin Topical: MedlinePlus Drug Information

How should Flucort N be stored and disposed of?

How to Store and Dispose of Flucort N Cream

Storage and disposal of Flucort N Cream must strictly adhere to regulatory labeling to maintain product stability and safety.

Official Storage Conditions

The cream must be stored at Controlled Room Temperature, typically between 15 C and 25 C (59 F and 77 F). It is mandatory to protect from freezing and avoid excessive heat above 40 C. The product should be kept in its original container, tightly closed, and stored away from moisture and direct light.

Safety and Disposal Requirements

For safety, the medication must be kept out of the sight and reach of children. Do not use the cream if it is expired or damaged. Unused or expired Flucort N must be properly discarded and not flushed down the toilet or poured into a drain unless specific guidance is provided by an official authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Flucort N found in:

A-Z Index: